vs
STANDARD BIOTOOLS INC.（LAB）与Stran & Company, Inc.（SWAG）财务数据对比。点击上方公司名可切换其他公司
Stran & Company, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.5倍（$28.9M vs $19.6M），Stran & Company, Inc.净利率更高（0.8% vs -177.4%，领先178.2%），Stran & Company, Inc.同比增速更快（7.2% vs -11.5%），Stran & Company, Inc.自由现金流更多（$38.0K vs $-23.1M），过去两年Stran & Company, Inc.的营收复合增速更高（24.0% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Stran & Company, Inc.是品牌促销产品、定制周边及一体化营销解决方案供应商，服务覆盖零售、医疗、科技、教育等领域企业客户，助力客户开展品牌宣传、用户运营及员工激励相关工作。
LAB vs SWAG — 直观对比
营收规模更大
SWAG
是对方的1.5倍
$19.6M
营收增速更快
SWAG
高出18.7%
-11.5%
净利率更高
SWAG
高出178.2%
-177.4%
自由现金流更多
SWAG
多$23.1M
$-23.1M
两年增速更快
SWAG
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $28.9M |
| 净利润 | $-34.7M | $243.0K |
| 毛利率 | 48.5% | 30.4% |
| 营业利润率 | -168.5% | -0.1% |
| 净利率 | -177.4% | 0.8% |
| 营收同比 | -11.5% | 7.2% |
| 净利润同比 | -28.8% | 141.5% |
| 每股收益（稀释后） | $-0.09 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSWAG
| Q4 25 | — | $28.9M | ||
| Q3 25 | $19.6M | $26.0M | ||
| Q2 25 | $21.8M | $32.6M | ||
| Q1 25 | $40.8M | $28.7M | ||
| Q4 24 | — | $27.0M | ||
| Q3 24 | $22.1M | $20.1M | ||
| Q2 24 | $22.5M | $16.7M | ||
| Q1 24 | $45.5M | $18.8M |
净利润LABSWAG
| Q4 25 | — | $243.0K | ||
| Q3 25 | $-34.7M | $-1.2M | ||
| Q2 25 | $-33.5M | $643.0K | ||
| Q1 25 | $-26.0M | $-393.0K | ||
| Q4 24 | — | $-586.0K | ||
| Q3 24 | $-26.9M | $-2.0M | ||
| Q2 24 | $-45.7M | $-1.0M | ||
| Q1 24 | $-32.2M | $-491.0K |
毛利率LABSWAG
| Q4 25 | — | 30.4% | ||
| Q3 25 | 48.5% | 27.2% | ||
| Q2 25 | 48.8% | 30.3% | ||
| Q1 25 | 48.4% | 29.6% | ||
| Q4 24 | — | 32.5% | ||
| Q3 24 | 54.9% | 29.5% | ||
| Q2 24 | 46.1% | 32.8% | ||
| Q1 24 | 53.1% | 29.8% |
营业利润率LABSWAG
| Q4 25 | — | -0.1% | ||
| Q3 25 | -168.5% | -6.9% | ||
| Q2 25 | -118.1% | 1.2% | ||
| Q1 25 | -80.8% | -1.9% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | -120.9% | -10.8% | ||
| Q2 24 | -134.5% | -6.6% | ||
| Q1 24 | -132.2% | -3.5% |
净利率LABSWAG
| Q4 25 | — | 0.8% | ||
| Q3 25 | -177.4% | -4.8% | ||
| Q2 25 | -153.7% | 2.0% | ||
| Q1 25 | -63.8% | -1.4% | ||
| Q4 24 | — | -2.2% | ||
| Q3 24 | -122.0% | -10.1% | ||
| Q2 24 | -203.3% | -6.1% | ||
| Q1 24 | -70.6% | -2.6% |
每股收益（稀释后）LABSWAG
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-0.09 | $-0.07 | ||
| Q2 25 | $-0.09 | $0.03 | ||
| Q1 25 | $-0.07 | $-0.02 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $-0.07 | $-0.11 | ||
| Q2 24 | $-0.12 | $-0.06 | ||
| Q1 24 | $-0.27 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $11.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $30.5M |
| 总资产 | $539.6M | $49.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSWAG
| Q4 25 | — | $11.6M | ||
| Q3 25 | $129.4M | $11.8M | ||
| Q2 25 | $158.6M | $18.1M | ||
| Q1 25 | $150.9M | $12.2M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | $210.6M | $6.9M | ||
| Q2 24 | $269.8M | $9.6M | ||
| Q1 24 | $287.1M | $10.7M |
总债务LABSWAG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSWAG
| Q4 25 | — | $30.5M | ||
| Q3 25 | $399.7M | $30.2M | ||
| Q2 25 | $424.5M | $31.8M | ||
| Q1 25 | $454.6M | $31.3M | ||
| Q4 24 | — | $31.6M | ||
| Q3 24 | $489.3M | $32.3M | ||
| Q2 24 | $510.3M | $34.3M | ||
| Q1 24 | $577.3M | $35.2M |
总资产LABSWAG
| Q4 25 | — | $49.3M | ||
| Q3 25 | $539.6M | $50.3M | ||
| Q2 25 | $557.0M | $61.2M | ||
| Q1 25 | $579.6M | $52.2M | ||
| Q4 24 | — | $55.1M | ||
| Q3 24 | $681.5M | $48.8M | ||
| Q2 24 | $708.7M | $46.6M | ||
| Q1 24 | $777.7M | $47.9M |
负债/权益比LABSWAG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $161.0K |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $38.0K |
| 自由现金流率自由现金流/营收 | -118.1% | 0.1% |
| 资本支出强度资本支出/营收 | 4.5% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 0.66× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-5.5M |
8季度趋势，按日历期对齐
经营现金流LABSWAG
| Q4 25 | — | $161.0K | ||
| Q3 25 | $-22.2M | $-5.4M | ||
| Q2 25 | $-20.7M | $6.4M | ||
| Q1 25 | $-30.3M | $-5.9M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | $-27.9M | $-2.7M | ||
| Q2 24 | $-39.0M | $2.1M | ||
| Q1 24 | $-62.5M | $2.1M |
自由现金流LABSWAG
| Q4 25 | — | $38.0K | ||
| Q3 25 | $-23.1M | $-5.9M | ||
| Q2 25 | $-22.6M | $6.3M | ||
| Q1 25 | $-35.3M | $-6.0M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-30.1M | $-2.9M | ||
| Q2 24 | $-41.0M | $1.9M | ||
| Q1 24 | $-63.3M | $1.9M |
自由现金流率LABSWAG
| Q4 25 | — | 0.1% | ||
| Q3 25 | -118.1% | -22.6% | ||
| Q2 25 | -103.6% | 19.5% | ||
| Q1 25 | -86.6% | -21.0% | ||
| Q4 24 | — | 4.6% | ||
| Q3 24 | -136.4% | -14.3% | ||
| Q2 24 | -182.2% | 11.6% | ||
| Q1 24 | -138.9% | 9.9% |
资本支出强度LABSWAG
| Q4 25 | — | 0.4% | ||
| Q3 25 | 4.5% | 1.9% | ||
| Q2 25 | 8.7% | 0.2% | ||
| Q1 25 | 12.4% | 0.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | 10.2% | 0.7% | ||
| Q2 24 | 8.6% | 1.1% | ||
| Q1 24 | 1.7% | 1.0% |
现金转化率LABSWAG
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 9.99× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SWAG
| Promotional Products Dropshipping | $11.2M | 39% |
| Casino Continuity Program | $6.9M | 24% |
| Promotional Products Company Owned Inventory | $4.6M | 16% |
| Promotional Products Bulk Dropshipping | $3.8M | 13% |
| Promotional Products Thirdparty Distributor | $1.8M | 6% |
| Other | $610.0K | 2% |
